Clinical research
What the science actually shows
Active trials and peer-reviewed studies, pulled straight from ClinicalTrials.gov and PubMed E-utilities. Updated daily. We summarize, we do not editorialize.
Active trials
30 listed- NCT07118839· 4d ago
MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder
The study investigators are conducting the first randomized placebo-controlled trial of MDMA-assisted therapy with a comorbid sample of military Veterans with a co-occurring diagnosis of Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). This novel experimental treatment package consists of three once-monthly Experimental Sessions of therapy combined with a divided-dose of MDMA HCl, along with non-drug preparatory and integrative therapy. The primary objective of the proposed project is to evaluate safety and clinical outcomes of MDMA-assisted therapy compared to identical psychotherapy with low dose ("active placebo") MDMA for the treatment of PTSD-AUD in military Veterans. The Primary Outcome measures, the Clinician Administered PTSD Scale (CAPS-5) and Inventory of Psy
mdma - NCT07288151· 2w ago
MDMA-Assisted Massed Exposure Therapy for PTSD
The goal of this clinical trial is to investigate the efficacy of 3,4-methylenedioxy-methamphetamine hydrochloride (MDMA) combined with Massed Prolonged Exposure (PE) therapy for the treatment of posttraumatic stress disorder (PTSD) in adult participants diagnosed with PTSD. This randomized, placebo-controlled trial will enroll 95 participants. The main questions it aims to answer are: * Does the combination of PE + MDMA lead to greater reduction in PTSD symptom severity from pre-treatment to one-month follow-up compared to PE + placebo? * Does PE + MDMA improve response efficiency and durability of PTSD symptom improvement compared to PE + placebo? * Does MDMA + PE enhance extinction retention and reduce amygdala threat reactivity, and are these changes associated with improved PTSD out
mdma - NCT06066853· 2w ago
MDMA-assisted Therapy for Fibromyalgia
Fibromyalgia is a debilitating chronic pain disorder. Based on prior research with MDMA, it can be hypothesized MDMA-assisted therapy in fibromyalgia patients may increase the range of positive emotions, interpersonal trust, and heighten the state of empathic rapport that can lead to an enhanced patient-clinician interaction and to initiate reattribution processes targeting dysfunctional thoughts towards pain. Therapeutic alliance, i.e. a positive patient-clinician relationship, is already acknowledged as an essential component for MDMA-assisted therapy. Despite its importance, the patient-clinician interaction and the neuroscience supporting patient/clinician therapeutic alliance has received almost no attention in MDMA research. The investigators will examine the potential therapeutic be
mdma - NCT07523334· 2w ago
Impact of Esketamine on Delayed Neurocognitive Recovery in Older Patients
Esketamine is frequently used during the perioperative period for supplemental analgesia. Small sample size trials showed that subanesthetic dose esketamine may decrease postoperative neurocognitive complications. However, conflicting results exist and optimal dose of esketamine remains to be determined. This dose-exploring pilot trial is designed to evaluate the safety and efficacy of three different perioperative esketamine dosing regimens in older patients undergoing major non-cardiac surgery. The primary purpose is to explore the optimal dosing strategy that produce maximal neurocognitive benefits with minimal adverse neuropsychiatric symptoms.
spravatoketamine ivketamine im - NCT05455996· 2w ago
MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers
The purpose of this study is to assess the safety and efficacy of MDMA-Assisted Therapy on Health Care Workers suffering from symptoms of Post-Traumatic Stress due to their work on the frontline of the COVID Pandemic.
mdma - NCT07444788· 2w ago
Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants
Participation in this study lasts approximately two weeks and includes three on-site study visits: a screening visit (approximately 2 hours), a study drug administration visit (approximately 4 hours), and a follow-up visit approximately one week later (approximately 2 hours). If participants decide to take part in the study and meet the inclusion and exclusion criteria, they will be randomly assigned to one of two groups: an experimental group or a control group. Participants will not be informed of your group assignment. Participants in the experimental group will receive the investigational substance 5-MeO-DMT at a dose of 0.2, 0.4, 0.6, or 0.8 mg/min for a total infusion duration of 30 min. Participants in the control group will receive a placebo that is indistinguishable in appearance
- NCT03606538· 3w ago
MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
The goal of this clinical trial to learn how MDMA is processed in people with abnormal liver function. The main questions it aims to answer are: Do people with abnormal liver function experience greater absorption of MDMA? Does the dose of MDMA need to be adjusted in people with abnormal liver function? Researchers will compare people with abnormal liver function to people with normal liver function. Participants will receive a single dose of MDMA then undergo periodic vitals measurements. They will remain at the study site for two more days undergoing more vitals measurements and having subjective effects and adverse events measured.
mdma - NCT07494214· 1mo ago
Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants
This study investigates whether MDMA may have a pain-reducing effect. The effect of MDMA is compared with a placebo (a substance with no active effect). In the study, moderate pain will be artificially created in healthy participants using repeated small electrical pulses applied under the skin. At the same time, participants will take MDMA or a placebo by mouth. This allows researchers to compare how MDMA affects the artificially created pain. A total of 20 healthy volunteers will take part in this study.
mdma - NCT07102576· 2mo ago
MDMA-Assisted Therapy for Mental Healthcare Providers
This is a phase 1, open-label study to assess changes in mental well-being following MDMA administration within a therapeutic setting, in mental health providers who are in training to become MDMA assisted therapists. Secondary outcome measures will examine the effects on provider burnout, provider self-efficacy, mood, self-compassion, quality of life, and other psychological factors. Participants will work with a co-therapy pair as they engage in a preparatory session, one experimental session with MDMA, and an integration session the following day.
mdma - NCT07399756· 2mo ago
Mitochondrial Function After Ketamine
The goal of this observational study is to learn about the role of mitochondria in response to S-ketamine. in individuals with Treatment-Resistant Depression. the Research Questions are 1. Does S-ketamine treatment modulate mitochondrial function in peripheral blood cells, as reflected by mitochondrial content and circulating mitochondrial biomarkers such as GDF15? 2. Can changes in mitochondrial function serve as biomarkers for predicting or monitoring clinical response to S-ketamine treatment? Samples will be collected at baseline, 3 hours after the first treatment, and 6 weeks post-exposure, and compared between responders and non-responders
ketamine ivketamine imketamine oral - NCT07369102· 2mo ago
Esketamine With or Without Integration Therapy for Treatment-Resistant Depression
This study will explore the effects of esketamine (Spravato®), an FDA-approved nasal spray, on adults diagnosed with treatment-resistant depression (TRD). All participants will receive esketamine as prescribed by a healthcare professional in a clinical setting. The purpose of this research is to understand whether adding therapeutic support in the form of preparation and integration sessions - before and after the esketamine doses - can enhance the treatment experience and lead to longer-lasting improvements in mood and functioning. Participants will be randomly assigned to one of two groups: Esketamine with therapeutic support sessions (integration group) Esketamine without additional support (standard care group) Both groups will receive standard monitoring and psychiatric evaluation
spravatoketamine ivketamine im - NCT07301632· 2mo ago
Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial
This is a Health Canada regulated internal pilot study designed to assess the feasibility, tolerability, and preliminary efficacy of 3, 4-methylenedioxymethamphetamine hydrochloride capsules-AT for chronic neuropathic pain to inform a larger, fully powered multi-center study. This is an interventional, randomized, 2-arm parallel, triple blinded study. The total study duration is 2 years. Participants will receive preparatory psychotherapy session during week 2 and week 4 followed by a combined single dosing session with psychotherapy during week 6. Integrative psychotherapy will follow at weeks 6, 8, 12, and 16. Follow up for primary clinical endpoint at week 16; final follow up for secondary clinical endpoint at 16-weeks. Participants will be asked to complete adjunctive home psychoth
- NCT07469098· 3mo ago
Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events
The goal of this clinical trial is to evaluate the safety, tolerability and effectiveness of group-based MDMA-assisted therapy compared to individual MDMA-assisted therapy in participants with PTSD, who were diagnosed following the events of 7 October 2023. The main questions it aims to answer are: safety and tolerability? effectiveness? Researchers will compare group-based MDMA-assisted therapy to individual MDMA-assisted therapy to see if group-based MDMA-assisted therapy is not inferior to individual MDMA-assisted therapy, in terms of safety and effectiveness. Participants will be randomized to one of two study arms: group-based MDMA-assisted therapy or individual MDMA-assisted therapy receive MDMA HCl administered orally in a divided dose. Participate in preparatory sessions, MDMA dos
mdma - NCT07317232· 4mo ago
Ayahuasca, Esketamine and Premenstrual Symptoms
Double-blind, randomized trial comparing a single dose of oral ayahuasca or esketamine on premenstrual symptoms.
spravatoketamine ivketamine im - NCT07317206· 4mo ago
Ayahuasca, Esketamine and PTSD
Double-blind, randomized trial comparing a single dose of oral ayahuasca or esketamine in patients with posttraumatic stress disorder.
spravatoketamine ivketamine im - NCT07303907· 4mo ago
A Phase 2A Trial of DT402 for Autism Spectrum Disorder
A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder
- NCT06989957· 7mo ago
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD). To apply or learn more, please view our website: https://hopkinspsychedelic.org/pamvet
psilocybin orpsilocybin comdma - NCT07179913· 7mo ago
The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression
The aim of this study is to observe the antidepressant effect of low-dose esketamine in obese patients with preoperative depression and seeking bariatric surgery. We speculate that intraoperative infusion and the addition of a small dose of esketamine to the postoperative analgesic pump can help reduce the proportion of patients with depression after surgery, and may further improve postoperative recovery, reduce the use of postoperative opioids, shorten postoperative hospital stay, and improve postoperative quality of life of patients.
spravatoketamine ivketamine im - NCT05783817· 7mo ago
MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
The study assesses the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).
mdma - NCT06683014· 7mo ago
MDMA in Borderline Personality Disorder
The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.
mdma - NCT06905652· 8mo ago
Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants
Racemic ±3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others. These acute subjective effects of MDMA may be helpful to assist psychotherapy and MDMA has been investigated in phase 3 trials as a possible treatment in post-traumatic stress disorder.
mdma - NCT06418178· 10mo ago
Dose Optimization of MDMA-Assisted Therapy for PTSD
This open label, within-subjects dose optimization trial will investigate the optimal number of MDMA-Assisted Therapy treatment cycles (i.e., one MDMA session and three integration sessions) in a sample of U.S. veterans with PTSD. Participants will complete from one to five cycles of MDMA-AT.
mdma - NCT06884514· 1y ago
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
The acute subjective effects of serotonin (5-HT)2A receptor stimulation with psilocybin in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking, or loss of trust towards other people are common effects, depending on the dose administered, the personality traits of the person consuming it (set), or the environment in which psilocybin is taken (setting). Negative psychedelic effects may cause acute distress to the subject and acute anxiety has been linked to less favorable long-term outcomes in patients experimentally treated with psilocybin or similar substances for the treatment of depression. The 5-HT and oxytocin releaser 3,4-methylenedioxymethamphetamine (MDMA) reliably induces positive mood, euphoria, comfort, empathy, and feelings of trust. If admin
psilocybin orpsilocybin comdma - NCT05770375· 1y ago
Tolerability of MDMA in Schizophrenia
Impaired social motivation, or "asociality," is a negative symptom of schizophrenia (SCZ) and a cause of significant functional impairment in the illness. Whereas many symptoms of schizophrenia can be treated with antipsychotic medications, deficits in social motivation persist, leading to significant social disability in patients. There is currently no effective treatment for this symptom of the illness. One promising and unexplored avenue to enhance social motivation in schizophrenia is ± 3,4-methylenedioxymethamphetamine (MDMA). MDMA is a psychostimulant that shares some pharmacological properties with amphetamines, but in addition, has pronounced pro-social effects, increasing the motivation to engage socially. In healthy volunteers, it produces feelings of empathy and closeness with o
mdma - NCT07050212· 1y ago
Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation
By comparing the application effects of three drugs in pediatric preoperative sedation, this study explores the optimal medication regimen, aiming to provide safer, more effective, and more personalized medication options for pediatric preoperative sedation. Additionally, this research will also focus on the impact of these three drugs on postoperative agitation in children, offering valuable references for the overall management of pediatric surgical anesthesia.
spravatoketamine ivketamine im - NCT05790239· 1y ago
MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder
This randomized, double-blind, single-site phase II 2-arm study will investigate the safety and preliminary efficacy of MDMA-assisted therapy compared with low dose d-amphetamine-assisted therapy on the severity of PTSD symptoms in participants aged 18 years and older with PTSD of at least moderate severity.
mdma - NCT05837845· 1y ago
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
In partnership with the Veterans Affairs (VA) Palo Alto Health Care System and Stanford University, this study aims to evaluate clinical outcomes, assess implementation feasibility, and health economics of MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) in the treatment of posttraumatic stress disorder (PTSD). Through a randomized comparison of MDMA-aCPT versus Cognitive Processing Therapy (CPT), a VA gold standard treatment for PTSD, the proposed study will set the stage for understanding the potential use and application of MDMA-aCPT for PTSD within the VA system.
mdma - NCT06772753· 1y ago
Investigation of Psychedelic Effects in Psychoactive Substances
The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics. Screening involves a medical and psychiatric examination, including blood draw, history and physical, interviews, and questionnaires. Eligible participants will then be asked to complete up to 6 experimental drug administration session during which the participants will potentially receive and report on the subjective effects of 6 different psychoactive substances or inactive placebo. Drug assignment for some sessions will be randomized (like flipping a count or rolling a pair of dice), and both participants and study staff will be blind to the drug condition on any given day. Participants will al
- NCT06713616· 1y ago
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
The purpose of this study is to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for use in the treatment of treatment-resistant depression (TRD) and Esketamine (Spravato®), taken as a nasal spray which has received FDA approval for use in the treatment of treatment-resistant depression (TRD) in the treatment of patients with treatment-resistant depression (TRD). The study will look at the following: * How well the treatment helps with symptoms of depression (effectiveness), * How comfortable and willing people are to use the treatment (acceptability), and * How well people can deal with any side effects from the treatment (tolerability). The study will also examine factors th
spravatoketamine ivketamine im - NCT06789705· 1y ago
Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls
The investigator hypothesize that low-dose MDMA (3,4-methylenedioxymethamphetamine) will produce a sufficiently strong oxytocin stimulation in healthy controls and no relevant increase in patients. This study will confirm previously published data and provide important safety data with low-dose MDMA stimulation testing.
mdma
Recent publications
30 listed- PubMedPMID 41919730· today
Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.
Published 2026 Dec in Eur J Psychotraumatol. Authors: Rothärmel M, Mekaoui L, Kazour F et al.
- PubMedPMID 41814842· today
Perioperative Ketamine and Esketamine for Enhanced Recovery After Surgery (ERAS): A Systematic Review.
Published 2026 Dec in J Invest Surg. Authors: Xu M, Zhu R, She YJ et al.
- PubMedPMID 41810848· today
High-flow versus standard nasal cannula oxygenation for post-procedural quality of recovery in older adults undergoing sedated ERCP: protocol for a randomized controlled trial.
Published 2026 Dec in Ann Med. Authors: Huang L, Gui WH, Zhu Y et al.
- PubMedPMID 41663054· today
Letter regarding "efficacy of esketamine in reducing nausea and vomiting after anesthesia: a systematic review and meta-analysis of randomized controlled trials".
Published 2026 Dec in Ann Med. Authors: Mao M, Chen J
- PubMedPMID 41630466· today
Letter to the editor regarding: Efficacy of esketamine in reducing nausea and vomiting after anesthesia: a systematic review and meta-analysis of randomized controlled trials.
Published 2026 Dec in Ann Med. Authors: Xia JY, Shen QH
- PubMedPMID 41607108· today
Effects of nine sedative-analgesic combinations on fatigue after gastrointestinal endoscopy: a randomized controlled 3 × 3 factorial trial protocol.
Published 2026 Dec in Ann Med. Authors: Huang L, Xu LN, Kuai LY et al.
- PubMedPMID 41454547· today
Efficacy of esketamine in reducing nausea and vomiting after anesthesia: a systematic review and meta-analysis of randomized controlled trials.
Published 2026 Dec in Ann Med. Authors: Tang L, Qu S, Du Z et al.
- PubMedPMID 41881122· today
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.
Published 2026 Aug 1 in J Affect Disord. Authors: Goodwin GM, Aaronson ST, Alvarez O et al.
- PubMedPMID 41876058· today
Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis.
Published 2026 Aug 1 in J Affect Disord. Authors: Kishi T, Sakuma K, Hatano M et al.
- PubMedPMID 41933621· today
Role of concomitant benzodiazepines, lithium, and lamotrigine in modulating the antidepressant effects of subcutaneous esketamine in patients with treatment-resistant depressive episodes: A retrospective naturalistic study.
Published 2026 Aug 1 in J Affect Disord. Authors: Atidio JP, Delfino RS, Garios IS et al.
- PubMedPMID 41740756· today
Comparative effectiveness and safety of esketamine versus injectable racemic ketamine and oral antidepressants for major depressive disorder: A population-based target trial emulation.
Published 2026 Aug 1 in J Affect Disord. Authors: Lee CJ, Qian Y, Yu W et al.
- PubMedPMID 41796776· today
Assessing the presence of biasing and non-biasing unblinding in a randomized controlled trial of a home-use tDCS device: An exploratory analysis.
Published 2026 Jul 15 in J Affect Disord. Authors: Hieronymus F, Huneke NTM, Månsson D et al.
- PubMedPMID 41765237· today
Predictors of responsiveness to ketamine: An updated systematic review of neuroimaging findings.
Published 2026 Jul 15 in J Affect Disord. Authors: Kiani I, Cattarinussi G, Sambataro F et al.
- PubMedPMID 41934744· today
Attentional bias to death-related stimuli: Modeling cortical dynamics underlying suicide risk.
Published 2026 Jul in Psychiatry Res Neuroimaging. Authors: Lee Y, Gilbert JR, Lamontagne SJ et al.
- PubMedPMID 41881297· today
N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine.
Published 2026 Jul 1 in Neuropharmacology. Authors: de Sousa-Silva AN, Moura CA, de Oliveira Torres CI et al.
- PubMedPMID 41690631· today
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression.
Published 2026 Jun 15 in J Affect Disord. Authors: Kaczmarek ES, Rodrigues NB, Chisamore N et al.
- PubMedPMID 41707717· today
Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial.
Published 2026 Jun 15 in J Affect Disord. Authors: Weintraub MJ, Jeffrey JK, Ichinose MC et al.
- PubMedPMID 41740751· today
Multiple peripheral inflammatory markers in adolescents with major depressive disorder treated with repeated esketamine infusions: results from a randomized controlled trial.
Published 2026 Jun 15 in J Affect Disord. Authors: Lan X, Wu Z, Wang C et al.
- PubMedPMID 41698615· today
Ketamine ameliorates postpartum depression-like behaviors in rats exposed to sevoflurane during pregnancy through the AMPK/SIRT1/NLRP3 pathway.
Published 2026 Jun 15 in J Affect Disord. Authors: Xue H, Yang X, Kuai S et al.
- PubMedPMID 41830808· today
Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review.
Published 2026 Jun in Schizophr Res. Authors: Sabé M, Grof P, Sackett NB et al.
- PubMedPMID 41723946· today
Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health.
Published 2026 Jun in Addict Behav. Authors: Ehmann S, Hager NM, Regier PS et al.
- PubMedPMID 41916215· today
Letter to editor regarding "Efficacy of esketamine after cesarean section for women with symptoms of prenatal depression: A randomized controlled trial".
Published 2026 Jun in Psychiatry Res. Authors: Li Y, Ding X
- PubMedPMID 41831252· today
Effectiveness and factors associated with esketamine response during the 4-week induction period for treatment-resistant depression: post-hoc analysis of the real-world ESKALE study.
Published 2026 Jun in J Psychiatr Res. Authors: Samalin L, Rothärmel M, Mekaoui L et al.
- PubMedPMID 41763189· today
The effect of glutamatergic modulators on sleep behavior and architecture in depressive disorders: A systematic review.
Published 2026 Jun in J Psychiatr Res. Authors: Valentino K, Ballum H, Cheung W et al.
- PubMedPMID 41762896· today
Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.
Published 2026 Jun in Eur Neuropsychopharmacol. Authors: Reif A, Anıl YA, Bitter I et al.
- PubMedPMID 41651241· today
Age-related moderation of adjunctive psychotherapy and early life stress effects on depression symptom reductions following ketamine treatment: Initial insights from a large, naturalistic sample.
Published 2026 Jun 1 in J Affect Disord. Authors: Kosted R, Waddell A, Adolph K et al.
- PubMedPMID 41651238· today
Recommendations for repeated dosings of ketamine/esketamine rest on an uncertain evidence base. Response to.
Published 2026 Jun 1 in J Affect Disord. Authors: Plöderl M, Naudet F
- PubMedPMID 41621446· today
Multimodal rapid anti-depression: Esketamine combined with dexmedetomidine patient-controlled sleep for treatment-resistant depression - A retrospective study.
Published 2026 May 15 in J Affect Disord. Authors: Li YZ, Zhao CQ, Zuo MY et al.
- PubMedPMID 41616859· today
Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies.
Published 2026 May 15 in J Affect Disord. Authors: de Oliveira Lapa C, Viola T, Delfino R et al.
- PubMedPMID 41651039· today
Rapid antidepressant effects of Aurantii Fructus are mediated by hypoxanthine-caspase-4 axis in CUMS mice.
Published 2026 May 10 in J Ethnopharmacol. Authors: Lu C, Tian L, Wei Z et al.
Research cards link to the primary source. LicensedPsychedelics does not reproduce abstracts beyond the API-supplied summary field.